The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...

In the trial, people with diabetic macular edema who received Susvimo refilled every six months achieved noninferior improvements in vision compared with those receiving monthly 0.5-mg ranibizumab ...

It is a good test for screening for the development of "wet" macular degeneration in patients with "dry" macular degeneration.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Methods Participants were recruited from the Singapore Epidemiology of Eye Diseases Study ... retinal laser photocoagulation or retinal surgery; macular oedema based on fundus photography and OCT; ...

5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema ... (9.6 and 9.4 eye chart letters, respectively).